Seqirus’ Audenz Receives the US FDA’s Approval as the First Adjuvanted Cell-Based Pandemic Influenza A (H5N1) Vaccine

 Seqirus’ Audenz Receives the US FDA’s Approval as the First Adjuvanted Cell-Based Pandemic Influenza A (H5N1) Vaccine

Seqirus; Audenz; Receives; US; FDA; Approval; First; Adjuvanted; Cell-Based; Pandemic; Influenza A; H5N1 Vaccine

Shots:

  • The US FDA has approved Audenz (Influenza A (H5N1) monovalent vaccine, adjuvanted) to protect patients aged ≥6mos. against influenza A
  • The novel vaccine combines two technologies i.e, MF59 adjuvant and cell-based antigen manufacturing. The MF59 adjuvant and formulated prefilled syringes used in the Audenz vaccine, produced in the facility at Holly Springs, NC, supported by its partnership with the BARDA
  • Audenz is the first and only adjuvanted, cell-based pandemic vaccine, designed to provide active immunization against the influenza A virus H5N1 strain and has received FDA’s FT designation to prevent pandemic influenza caused by A (H5N1) virus in Dec’2015

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: WRAL Techwire

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post